Mitrix Bio CEO and Founder on mitochondrial degradation – and how it drives aging and lifespan.
DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal – https://longevity.technology/investment/dashboard/
Mitochondrial dysfunction has been implicated in dozens of chronic diseases from Alzheimer’s to CVD and from frailty to immune senescence. Californian longevity biotech start-up Mitrix Bio is targeting that dysfunction with its novel mitlets platform.
To tackle something, you have to understand it. We sat down with Mitrix Bio CEO and founder Tom Benson to get the lowdown on mitochondria, mitochondrial dysfunction and the mitochondrial cycle. It turns out that when it comes to mitochondrial replication, sometimes slow and steady really does win the longevity race.
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
Linkedin – https://bit.ly/3yIfDmf